CTOs on the Move

Visus Therapeutics

www.visustx.com

 
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion
  • www.visustx.com
  • 2 Nickerson Street Suite 101
    Seattle, WA USA 98109
  • Phone: 800.281.4536

Executives

Name Title Contact Details

Funding

Visus Therapeutics raised $36M on 03/09/2021

Similar Companies

Aeras Global TB Vaccine Foundation

Aeras is constantly producing new constructs that will also be made available following phenotypic, genotypic and stability characterization. Aeras is also glad to provide shigella carrier strains with capsids expressing TB antigens under similar

Strativa Pharmaceuticals

Strativa Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncopeptides AB

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers.

Lyne Laboratories

Lyne Laboratories is a Brockton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sonovion Pharmaceuticals

Sonovion Pharmaceuticals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.